Author | Gesto, João Silveira Moledo | |
Author | Cabanelas, Adriana | |
Author | Farjun, Bruna | |
Author | Santos, Monique Cristina dos | |
Author | Fidalgo Neto, Antonio A. | |
Author | Kuriyama, Sergio N. | |
Author | Souza, Thiago Moreno L. | |
Access date | 2022-10-21T18:20:20Z | |
Available date | 2022-10-21T18:20:20Z | |
Document date | 2022 | |
Citation | GESTO, João Silveira Moledo et al. Implemented occupational health surveillance limits the spread of SARS-CoV-2 Omicron at the workplace. Frontiers in Medicine, v. 9, 910176, p. 1 - 9, Aug. 2022. | en_US |
ISSN | 2298-858X | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/55238 | |
Language | eng | en_US |
Publisher | Frontiers Media | en_US |
Rights | open access | |
Subject in Portuguese | COVID-19 | en_US |
Subject in Portuguese | SARS-CoV-2 | en_US |
Subject in Portuguese | Saúde ocupacional | en_US |
Subject in Portuguese | Sequenciamento de próxima geração | en_US |
Subject in Portuguese | NGS | en_US |
Subject in Portuguese | Vigilância genômica | en_US |
Title | Implemented occupational health surveillance limits the spread of SARS-CoV-2 Omicron at the workplace | en_US |
Type | Article | |
DOI | 10.3389/fmed.2022.910176 | |
Abstract | The global spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has put an enormous pressure on human societies, at both
health and economic levels. Early diagnosis of SARS-CoV-2, the causative
agent of 2019 coronavirus disease (COVID-19), has proved an efficient
method to rapidly isolate positive individuals and reduce transmission rates,
thus alleviating its negative impact on society’s well-being and economic
growth. In this work, through a coordinated and centralized effort to monitor
SARS-CoV-2 circulation in companies from the State of Rio de Janeiro, Brazil,
we have detected and linked an early rise of infection rates in January 2022 to
the introduction of the Omicron variant of concern (VoC) (BA.1). Interestingly,
when the Omicron genomic isolates were compared to correlates from public
datasets, it was revealed that introduction events were multiple, with possible
migration routes mapping to: Mali; Oman and United States; and Italy, Latin
America, and United States. In addition, we have built a haplotype network
with our genomic dataset and found no strong evidence of transmission
chains, between and within companies. Considering Omicron’s particularly
high transmissibility, and that most of our samples (>87%) arose from 3 out of
10 companies, these findings suggest that workers from such environments
were exposed to SARS-CoV-2 outside their company boundaries. Thus,
using a mixed strategy in which quick molecular diagnosis finds support
in comprehensive genomic analysis, we have shown that a successfully
implemented occupational health program should contribute to document
emerging VoC and to limit the spread of SARS-CoV-2 at the workplace. | en_US |
Affilliation | SESI Innovation Center for Occupational Health. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | SESI Innovation Center for Occupational Health. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | SESI Innovation Center for Occupational Health. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | SENAI Innovation Institute for Green Chemistry. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | SENAI Innovation Institute for Green Chemistry. Rio de Janeiro, RJ, Brasil / SESI Innovation Center for Occupational Health. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | SESI Innovation Center for Occupational Health. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil / National Institute of Science and Technology for Innovation on Diseases of Neglected Populations (INCT/IDN), Rio de Janeiro, Brazil. | en_US |
Subject | COVID-19 | en_US |
Subject | SARS-CoV-2 | en_US |
Subject | Occupational health | en_US |
Subject | Next generation sequencing | en_US |
Subject | NGS | en_US |
Subject | Genomic surveillance | en_US |